Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
A subgroup analysis of a randomized study demonstrated that patients with advanced or metastatic liposarcoma treated with eribulin had longer overall survival and progression-free survival compared to those treated with dacarbazine, suggesting eribulin as a therapeutic option for advanced liposarcoma. Therefore, this study aims to evaluate the cost...
Alternative Titles
Full title
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4de9883cd811462bb3725b586c11788e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4de9883cd811462bb3725b586c11788e
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-024-84247-w
